Straumann and Nobel Biocare are reportedly no longer interested in purchasing Astra Tech, the dental implant division of AstraZeneca, according to a story by Reuters.
AstraZeneca is hoping to sell Astra Tech for around $2 billion. The deal has attracted a plethora of bidders in recent months, including Straumann, Nobel Biocare, Zimmer, Dentsply, Danaher, and several private equity firms.
Astra Tech had revenues of $535 million in 2010 and is the world’s third-largest dental implants maker after Straumann and Nobel Biocare, according to Reuters.
